Subscribe free

Newsletter

HPB & Spleen

Every new paper in this field, in your inbox.

FreeNo spamOne-click unsubscribe
Ann Surg22 Aug 2024

Adjusted ISGPS model enhances prediction of pancreatic fistulas.

The study validated the ISGPS classification to predict clinically relevant pancreatic fistula (CRPF) risk in 1,422 patients undergoing pancreatoduodenectomy for periampullary tumors. The CRPF rate was 22.2%, with a higher rate of 25.8% for periampullary tumors. Although the original ISGPS model showed moderate performance (AUC=0.632),…

Surg Today21 Aug 2024

Combination therapy improves survival in unresectable upper biliary tract cancers

A retrospective study of 60 patients with unresectable upper biliary tract cancer revealed that gemcitabine and cisplatin plus S-1 (GCS) therapy, followed by conversion surgery, significantly increased median overall survival to 28 months compared to 12.4 months for those receiving only GCS. The response rate…

Ann Surg Oncol20 Aug 2024

Innovative protocol enables high compliance in genetic testing

A novel protocol for germline genetic testing (GGT) in pancreatic ductal adenocarcinoma (PDAC) demonstrated a high patient compliance rate of 98.7%, with 310 patients tested over three years. The physician compliance rate was 82.6%, and 14.2% of patients had actionable pathogenic variants. The protocol effectively…

HPB & Spleen20 Aug 2024

Adipose-derived stem cells enhance pancreatic islet revascularization.

Co-transplantation of adipose tissue-derived mesenchymal stem cells (ADMSCs) with pancreatic islets into decellularized pancreatic skeletons improved vascularization and preserved islet morphology. While ADMSCs did not suppress immune responses in vivo, their presence reduced the proliferation of splenocytes in vitro. In contrast, endothelial cell co-transplantation resulted…

HPB & Spleen19 Aug 2024

Nomogram effectively predicts liver metastasis in colorectal cancer

A nomogram combining circulating tumor cells (CTC) from the first drainage vein and clinical parameters was developed to predict liver metastasis in colorectal cancer (CRC) patients. Analysis of data from 343 patients revealed that higher CTC levels correlated with liver metastasis. Key identified predictors included…

Langenbecks Arch Surg19 Aug 2024

Minor resections may be preferred for large hepatocellular carcinoma

A multicenter study analyzed 535 patients with single large hepatocellular carcinoma (slhcc). Results indicated that major hepatectomy led to significantly higher major complications and no long-term survival benefits compared to minor resections, especially left lateral sectionectomy, which was associated with better overall survival (p=0.02). The…

Ann Surg Oncol17 Aug 2024

Body composition changes during therapy influence pancreatic cancer survival.

A study involving 138 pancreatic cancer patients revealed that increases in muscle mass (over 5%) and adipose tissue (over 15%) during neoadjuvant therapy were linked to improved survival rates (hazard ratios of 0.352 and 0.375, respectively). Conversely, a loss of visceral fat exceeding 15% adversely…

BJS Open16 Aug 2024

Inadequate surgical treatment affects non-functioning pancreatic neuroendocrine tumours.

A retrospective study of 384 patients undergoing surgery for non-functioning pancreatic neuroendocrine tumours revealed that 40% received potentially inadequate treatment. Of these, 34% experienced potential overtreatment while 6% were potentially undertreated. Key predictors of overtreatment included smaller tumour sizes and earlier surgical intervention, while larger…

Acta Cir Bras15 Aug 2024

A new technique may reduce bile duct injury during surgery

The shoeshine technique enhances safety in laparoscopic cholecystectomy by achieving atraumatic exposure of the hepatocystic area and improving visibility in Calot's triangle. This method, utilized in over 2,000 cases by the authors, demonstrated effectiveness in reducing risks of bile duct injuries. By employing a blunt…

Int J Surg13 Aug 2024

HAIC treatment shows potential benefits over Sorafenib for HCC

Analysis of 26 studies involving 6456 hepatocellular carcinoma (HCC) patients demonstrated that hepatic artery infusion chemotherapy (HAIC) consistently outperformed Sorafenib in overall survival (OS) outcomes, except for those refractory to trans-arterial chemoembolization. Key risk factors for reduced OS included larger tumor size and heavier tumor…